title: Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus.
abstract: A 34-year old male renal transplant recipient developed thrombotic microangiopathy (Hemolytic Uremic Syndrome) in the early post-transplant period following combined immuno-suppressive therapy with tacrolimus and everolimus. The management consisted of discontinuation of tacrolimus and substitution with mycophenolate mofetil. His renal functions improved, the hematological abnormalities reversed and he continues to have good graft function one year later.
authors.affiliation: Sri Ramachandra Medical College and Research Institute, Chennai, India.
authors.forename: Balaji
authors.initials: B
authors.lastname: Pratap
authors.forename: Georgi
authors.initials: G
authors.lastname: Abraham
authors.forename: C N
authors.initials: CN
authors.lastname: Srinivas
authors.forename: Shanmuga
authors.initials: S
authors.lastname: Bhaskar
mesh_terms: D000328:Adult; D001706:Biopsy; D004359:Drug Therapy, Combination; D000068338:Everolimus; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011355:Prodrugs; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D011355:Prodrugs; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus